Nice | Empagliflozin in Type 2 Diabetes

This is a new guideline from Nice. Empagliflozin is a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, which blocks glucose reabsorption in the kidneys and so causes increased urinary excretion. For other SGLT-2 inhibitors have been approved by NICE, see my posts about Dapagliflozin and Canagliflozin. Empagliflozin use in Type 2 Diabetes as a 2nd drug in…
Read more

Nice | Canagliflozin in Type 2 diabetes

This new guideline from NICE outlines when canagliflozin can be used. This is an SGLT2 inhibitor (selective sodium-glucose cotransporter-2). It blocks reabsorption of glucose in the kidneys, so increases secretion. It's trade name is Invokana. Another one of these drugs (Dapagliflozin) was approved last year. When can it be used?  As a second drug added on to metformin…
Read more

BASHH | Use of androgens

Guidelines on the management of sexual problems in men and women – the use of androgens These are short and worth a read – there are useful summaries on the back pages. They encourage screening men and women at risk of sexual problems and advise when checking testosterone is useful (which is our job). It…
Read more